lunes, 21 de septiembre de 2020

New drug combo extends survival with advanced kidney cancer - STAT

New drug combo extends survival with advanced kidney cancer - STAT

The Readout

Damian Garde & Meghana Keshavan

A spate of combination approaches to kidney cancer

A combination therapy from Bristol Myers Squibb and Exelixis could help extend the lives of patients with kidney cancer compared to an older medicine, new data from ESMO show — but it’s not the only next-gen treatment option that shows this sort of efficacy.

Opdivo, the immunotherapy from BMS, and Cabometyx, a targeted cancer drug, reduced the risk of death by 40% in a Phase 3 trial as compared to Sutent, an old Pfizer drug for kidney cancer, STAT’s Adam Feuerstein writes. It also reduced the risk of disease progression by 49% compared to the older drug. 

No hay comentarios: